Drug Safety Alerts
Domperidon related Serious Cardiac Events in Children under 12 years of age!
European Medicines Agency (EMA) and the National Agency for Drug Safety (ANSM) have confirmed the risk of serious adverse cardiac events associated with the use of Domperidon including QT prolongation, torsade de pointes, ventricular arrhythmias and sudden cardiac death. The use of Domperidon is now restricted to adults and adolescents over 20 years of age and weighing more than 35kg. The recommended maximum dose is 35mg/day. The duration of treatment should be as short as possible.
All Healthcare Professionals are advised to monitor patients taking Domperidon and caution should be observed in Patients. In case such event is observed, please report to PDCU through mss.Punjab.gov.pk/
Primary & Secondary Healthcare Department,
Govt. of the Punjab